Memapsin 2 (beta-secretase) inhibitors: Drug development

Current Alzheimer Research

Volumn 5, Issue 2, 2008, Pages 121-131

  Ghosh, Arun K ^a   Kumaragurubaran, Nagaswamy ^a   Hong, Ling ^b   Koelsh, Gerald ^b   Tang, Jordan ^c,d  

^a PURDUE UNIVERSITY   (United States)

^b CoMentis Inc ^*  (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIDE; AMINE; AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SECRETASE INHIBITOR; CMT 21166; GUANIDINE DERIVATIVE; ISONICOTINAMIDE; MACROCYCLIC COMPOUND; OM 00 3; OM 003 DR9; OM 99 1; OM 99 2; OXADIAZOLE DERIVATIVE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CELL MEMBRANE; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG DESIGN; DRUG PENETRATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME INHIBITION; ENZYME STRUCTURE; ENZYME SUBSTRATE; EXPERIMENTAL ANIMAL; HUMAN; IC 50; MOLECULAR CLONING; NERVE CELL CULTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; STRUCTURE ACTIVITY RELATION;

ALZHEIMER DISEASE; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ASPARTIC ENDOPEPTIDASES; BINDING SITES; ENZYME INHIBITORS; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION;

EID: 42149166766     PISSN: 15672050     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720508783954730     Document Type: Review

References (47)

1. Lin, X, Koelsch G, Wu S , Downs D, Dashti A, and Tang J. Human aspartic protease memapsin 2 cleaves the beta-secretase site of beta-amyloid precursor protein. Proc Natl Acad Sci U S A 97: 1456-1460 (2000).
2. Vassar R, Bennett B D, Babu-Khan S, Kahn S, Mendiaz E A, Denis P, et al. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286: 735-741 (1999).
3. Yan R, Bienkowski M J, Shuck M E, Miao H, Tory M C, Pauley, A. M, et al. Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity. Nature 402: 533-537 (1999).
4. Sinha S, Anderson J P, Barbour R, Basi G S, Caccavello R, Davis D, et al. Purification and cloning of amyloid precursor protein beta-secretase from human brain. Nature 402: 537-540 (1999).
5. Hussain I, Powell D, Howlett D R, Tew D G, Meek T D, Chapman C, et al. Identification of a novel aspartic protease (Asp 2) as beta-secretase. Mol Cell Neurosci 14: 419-427 (1999).
6. Cai H, Wang Y, McCarthy D, Wen H , Borchelt D R, Price D L, et al. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons. Nat Neurosci 4: 233-234 (2001).
7. Luo Y, Bolon B, Kahn S, Bennett B D, Babu-Khan S, Denis P, et al. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation. Nat Neurosci 4: 231-232 (2001).
8. Roberds S L, Anderson J, Basi G, Bienkowski M J, Branstetter D G, et al. BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum Mol Genet 10: 1317-1324 (2001).
9. Ohno M, Sametsky E A, Younkin L H, Oakley H, Younkin S G, Citron M, et al. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of alzheimer's disease. Neuron 41: 27-33 (2004).
10. Harrison S M, Harper A J, Hawkins J, Duddy G, Grau E, Pugh P L, et al. BACE1 (beta-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol Cell Neurosci 24: 646-655 (2003).
11. Marciniszyn J, Jr, Hartsuck J A, and Tang J. Mode of inhibition of acid proteases by pepstatin. J Biol Chem 251: 7088-7094 (1976).
12. Chang W P, Koelsch G, Wong S, Downs D, Da H, Weerasena V, et al. In vivo inhibition of Abeta production by memapsin 2 (beta-secretase) inhibitors. J Neurochem 89: 1409-1416 (2004)
13. Chang W P, Downs D, Huang X P, Da H, Fung K M, and Tang, J. Amyloid-beta reduction by memapsin 2 (beta-secretase) immunization. FASEB J 21: 3184-3196 (2007).
14. rd, Koelsch G, Hong L, Castanheira P, Ermolieff J, Ghosh A K, et al. Subsite specificity of memapsin 2 (beta-secretase): implications for inhibitor design. Biochemistry 40: 10001-10006 (2001).
15. rd, Hong L, Koelsch G, Ghosh A K, and Tang J. Structural locations and functional roles of new subsites S5, S6, and S7 in memapsin 2 (beta-secretase). Biochemistry 44: 105-112 (2005).
16. Ghosh A K, Bilcer G, Hong L, Koelsch G and Tang J. Memapsin 2 (Beta-Secretase) Inhibitor Drug, between Fantasy and Reality. Curr Alzheimer Res 4, In press (2007).
17. Ghosh A K, Hong L, and Tang J. Beta-secretase as a therapeutic target for inhibitor drugs. Curr Med Chem 9: 1135-1144 (2002).
18. Ghosh A K, Kumaragurubaran N, and Tang J. Recent developments of structure based beta-secretase inhibitors for Alzheimer's disease. Curr Top Med Chem 5: 1609-1622 (2005).
19. Thompson L A, Bronson J J, and Zusi F C. Progress in the discovery of BACE inhibitors. Curr Pharm Des 11: 3383-3404 (2005).
20. John V. Human beta-secretase (BACE) and BACE inhibitors: progress report. Curr Top Med Chem 6: 569-578 (2006).
21. Durham T B, and Shepherd T A. Progress toward the discovery and development of efficacious BACE inhibitors. Curr Opin Drug Discov Devel 9: 776-791 (2006).
22. Hills I D, and Vacca J P. Progress toward a practical BACE-1 inhibitor. Curr Opin Drug Discov Devel 10: 383-391 (2007).
23. Hong L, Koelsch G, Lin X, Wu S, Terzyan S, Ghosh A K, et al. Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. Science 290: 150-153 (2000).
24. rd, Koelsch G, Shin D, Ghosh A K, and Tang J. Crystal structure of memapsin 2 (beta-secretase) in complex with an inhibitor OM00-3. Biochemistry 41: 10963-10967 (2002).
25. Ghosh A K, Shin D, Downs D, Koelsch G, Lin X, Ermolieff J, et al. Design of Potent Inhibitors for Human Brain Memapsin 2 (beta-Secretase). J Am Chem Soc 122: 3522-3523 (2000).
26. Ermolieff J, Loy J A, Koelsch G, and Tang J. Proteolytic activation of recombinant pro-memapsin 2 (Pro-beta-secretase) studied with new fluorogenic substrates. Biochemistry 39: 16263 (2000).
27. Ghosh A K, Bilcer G, Harwood C, Kawahama R, Shin D, Hussain K A, et al. Structure-based design: potent inhibitors of human brain memapsin 2 (beta-secretase). J Med Chem 44: 2865-2868 (2001).
28. Ghosh A K, Devasamudram T, Hong L, DeZutter C, Xu X, Weerasena V, et al. Structure-based design of cycloamide-urethane-derived novel inhibitors of human brain memapsin 2 (beta-secretase). Bioorg Med Chem Lett 15: 15-20 (2005).
29. Ghosh A K, Kumaragurubaran N, Hong L, Lei H, Hussain K A, Liu C F, et al. Design, synthesis and X-ray structure of protein-ligand complexes: important insight into selectivity of memapsin 2 (beta-secretase) inhibitors. J Am Chem Soc 128: 5310-5311 (2006).
30. Ghosh A K, Kumaragurubaran N, Hong L, Kulkarni S S, Xu X, Chang W, et al. Design, synthesis, and X-ray structure of potent memapsin 2 (beta-secretase) inhibitors with isophthalamide derivatives as the P2-P3-ligands. J Med Chem 50: 2399-2407 (2007).
31. Kawarabayashi T, Younkin L H, Saido T C, Shoji, M, Ashe K H, and Younkin S G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci 21: 372-381 (2001).
32. DeMattos R B, Bales K R, Cummins D J, Paul S M, and Holtzman D M. Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295: 2264-2267 (2002).
33. Rajapakse H A, Nantermet P G, Selnick H G, Munshi S, McGaughey G B, Lindsley S R, et al. Discovery of oxadiazoyl tertiary carbinamine inhibitors of β-secretase (BACE-1). J Med Chem 49: 7270-7273 (2006).
34. Lindsley S R, Moore K P, Rajapakse H A, Selnick H G, Young M B, Zhu H, et al. Design, synthesis and SAR of macrocyclic tertiary carbinamine BACE-1 inhibitors. Bioorg. Med Chem Lett 17: 4057-4061 (2007).
35. Stachel S J, Coburn C A, Sankaranarayanan S, Price E A, Pietrak B L, Huang Q, et al. Macrocyclic inhibitors of β-secretase: Functional activity in an animal model. J Med Chem 49: 6147-6150 (2006).
36. Stauffer S R, Stanton M G, Gregro A R, Steinbeiser M A, Shaffer J R, Nantermet P G, et al. Discovery and SAR of isonicotinamide BACE-1 inhibitors that bind β-secretase in a N-terminal 10s-loop down conformation. Bioorg. Med Chem Lett 17: 1788-1792 (2007).
37. Stanton M G, Stauffer S R, Gregro A R, Steinbeiser M A, Nantermet P G, Sankaranarayanan S, et al. Discovery of isonicotinamide derived β-secretase inhibitors: In vivo reduction of β-amyloid. J Med Chem 50: 3431-3433 (2007).
38. Maillard M C, Hom R K, Benson T E, Moon J B, Mamo S, Bienkowski M, et al. Design, Synthesis, and Crystal Structure of Hydroxyethyl Secondary Amine-Based Peptidomimetic Inhibitors of Human β-Secretase. J Med Chem 50: 776-781(2007).
39. Kimura T, Hamada Y, Stochaj M, Ikari H, Nagamine A, Abdel-Rahman H, et al. Design and synthesis of potent β-secretase (BACE1) inhibitors with P1' carboxylic acid bioisosteres. Bioorg Med Chem Lett 16: 2380-2386 (2006).
40. Hamada Y, Igawa N, Ikari H, Ziora Z, Nguyen J-T, Yamani A, et al. β-Secretase inhibitors: Modification at the P4 position and improvement of inhibitory activity in cultured cells. Bioorg Med Chem Lett 16: 4354-4359 (2006).
41. Freskos J N, Fobian Y M, Benson T E, Bienkowski M J, Brown D L, Emmons T, et al. Design of potent inhibitors of human β-Secretase. Part 1. Bioorg Med Chem Lett 17: 73-77 (2007).
42. Freskos J N, Fobian Y M, Benson T E, Moon J B, Bienkowski M J, Brown D L, et al. Design of potent inhibitors of human β-Secretase. Part 2. Bioorg Med Chem Lett 17: 78-81 (2007).
43. 2 hydroxyethylamine inhibitors of BACE1. Bioorg Med Chem Lett 17: 3378-3383 (2007).
44. Cole D C, Manas E S, Stock J R, Condon J S, Jennings L D, Aulaubaugh A, et al. Acylguanidines as small-molecule β-Secretase inhibitors. J Med Chem 49: 6158-6161 (2006).
45. Forbare W F, Solvibile W R, Robichaud A J, Malamas M S, Eric M, Turner J, Hu Y, et al. Thiophene substituted acylguanidines as BACE1 inhibitors. Bioorg Med Chem Lett 17: 5353-5356 (2007).
46. Baxter E W, Conway K A, Kennis L, Bischoff F, Mercken M H, Winter H L D, et al. 2-Amino-3,4-dihydroquinazolines as inhibitors of BACE-1 (β-site APP cleaving enzyme): Use of structure based design to convert a micromolar hit into a nanomolar hit. J Med Chem 50: 4261-4264 (2007).
47. http://www.athenagen.com/index.php?/athenagen/press_releases/45/